Related MeSH Hierarchy (5)
Diseases [C] » Infections [C01] » Respiratory Tract Infections » Pneumonia » Pneumonia, Viral » COVID-19
Diseases [C] » Infections [C01] » Virus Diseases » Pneumonia, Viral » COVID-19
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Nidovirales Infections » Coronaviridae Infections » Coronavirus Infections » COVID-19
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Pneumonia » Pneumonia, Viral » COVID-19
Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Infections » Pneumonia » Pneumonia, Viral » COVID-19
Description
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. MeSH
Hierarchy View
Phase 4 Indicated Drugs (139)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
3-(aminocarbonyl)-1-β-d-ribofuranosyl-pyridinium chloride
hydroxychloroquine (plaquenil)
inactivated SARS-Cov-2 vaccine
interferon alpha-2b (Intron-A)
interferon beta-1b (betaseron)
peginterferon beta-1a (Plegridy)
Phase 3 Indicated Drugs (238)
20-valent pneumococcal conjugate vaccine
acetylsalicylic acid (aspirin)
lanadelumab (shp643) (takhzyro)
liposomed heat-inactivated mycobacterium tuberculosis bacilli
recombinant covid-19 vaccine (cho cell)
recombinant covid-19 vaccine (sf9 cells)
recombinant new coronavirus vaccine (cho cell)
recombinant new coronavirus vaccine (cho cells)
sars-cov-2 fusion protein vaccine
sulfur hexafluoride lipid-type a microspheres (Lumason)
tenofovir alafenamide (genvoya)
Phase 2 Indicated Drugs (299)
adenovirus type-5 vectored covid-19 vaccine
allogeneic adipose derived mesenchymal stem cell
allogeneic bone marrow derived mesenchymal stem cell
allogeneic natural killer cells
allogenic mesenchymal stem cell derived from olfactory mucosa
antithrombin iii (human) (thrombate iii)
autologous mesenchymal stem cells
autologous non-hematopoietic peripheral blood stem cells
lv-smenp-dc vaccine and antigen-specific ctls
Mesenchymal Stem Cells Exosomes
pd-1 and ace2 knockout t cells
recombinant novel coronavirus vaccine (adenovirus type 5 vector)
Phase 1 Indicated Drugs (109)
Other Experimental Indicated Drugs (60)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
